Protein Misfolding in Neurodegenerative Diseases

Häftad, Engelska, 2025

1 678 kr

Beställningsvara. Skickas inom 7-10 vardagar. Fri frakt över 249 kr.

Beskrivning

Protein Misfolding in Neurodegenerative Diseases is a comprehensive review of proteome homeostasis in neurons, and in the brain. Beginning with an introduction on factors involved in the formation and aggregation of misfolded proteins, chapters then discuss the precise cellular and molecular mechanisms involved in these processes and their role in neurodegeneration and disease. Additional topics of focus include protein clearance mechanisms like protein quality control, disease-modifiers, molecular druggable targets, novel therapeutics, and emerging techniques that block or delay disease onset or progression. This volume is relevant for researchers working with neurodegenerative diseases, including Alzheimer's disease, Parkinson’s disease, ALS, Creutzfeldt-Jakob disease, and more.

Discusses underlying cellular and molecular mechanisms altered in protein-associated neurodegenerative disorders
Describes methods for detection and analysis of protein aggregates
Features advancements in therapeutics and emerging techniques to treat these disorders
Covers implications in a variety of neurodegenerative diseases, including Alzheimer's, Parkinson’s, ALS, Creutzfeldt-Jakob disease, Cystic fibrosis, Gaucher's disease, and Polyglutamine diseases, including Huntington’s and other related proteinopathies

Produktinformation

Utgivningsdatum:2025-03-20
Mått:152 x 229 x 30 mm
Vikt:900 g
Format:Häftad
Språk:Engelska
Antal sidor:574
Förlag:Elsevier Science
ISBN:9780443187162

Utforska kategorier

Patologi inom Medicin
Biovetenskap inom Naturvetenskap och teknik
Biologi inom Naturvetenskap och teknik

Mer om författaren

Dr. Gogia is a Post-Doctoral Associate at Yale. Having completed her PhD degree at the University of Dayton, and Cornell University’s International Agriculture and Rural Development Program (IARD) she was awarded the Gerald L. Willis Award of Excellence for Outstanding Teaching in 2019. Her current work focuses on understanding cellular and molecular mechanisms underlying polyglutamine diseases, namely the identification and validation of genetic modifiers which can serve as potential therapeutic targets and can ameliorate the onset or progression of neurodegenerative diseases. Dr. Sandeep Kumar Singh is Assistant Professor in the All India Institute of Medical Sciences (AIIMS), Nagpur, India. He obtained his PhD in Biotechnology from Banaras Hindu University and conducted postdoctoral research in the Department of Neurobiology at the University of Chicago. Dr. Singh brings 17 years of experience in neuroscience, molecular biology, neurodegenerative diseases, aging, nutraceuticals, and nanomedicines. He is a member of several scientific societies, including the American Academy of Neurology, International Society of Neurochemistry, Society of Neurochemistry, Indian Academy of Neurosciences, and Alzheimer’s and related Disorders Society of India. Dr. Singh has published five books, including Elsevier’s A New Era in Alzheimer’s Research and Genome Editing for Neurodegenerative Diseases.Vidyadhara Devarunda Jaganath works in the Department of Neurology and Neuroscience, Yale University School of Medicine, CT, USA.

Innehållsförteckning

1. Maintenance of balanced proteome homeostasis2. Determinants of protein misfolding, aggregation in neuronal cell death3. Classification, structure, and function of protein aggregates in proteinopathies4. Protein aggregation and cellular and molecular mechanisms in neurodegenerative disease5. Advances in methods to detect and study protein aggregation6. Organelle specific protein quality control7. Molecular chaperones and co-chaperones in proteostasis8. The ubiquitin-Proteasome System (UPS) and Autophagy lysosomal proteolytic pathways9. Alterations in protein quality control10. Alternate mechanisms to maintain proteome homeostasis11. Advances in developing novel therapeutics, strategies, approaches and use of emerging techniques12. Challenges in translating laboratory findings to drug development13. Advancements in drug delivery technologies for protein misfolding diseases